Afshin Rashtian, MD

Director of Radiation Oncology, CyberKnife Specialist: Dr. Afshin Rashtian

Previous to joining Newport Diagnostic Center, he was the Medical Director of Radiation Oncology at Riverside Community Hospital. He also served as Assistant Professor of Clinical Radiation Oncology at USC/Norris Cancer Hospital and USC/LAC, Associate Program Director of the Residency program at USC as well as the Medical School Clerkship Director. Dr. Rashtian was also the RTOG (Radiation Therapy Oncology Group) representative for USC. Dr. Rashtian received his B.S. in Biology from George Mason University in Virginia with honors. He was then awarded a grant for a research project at the NIH for two years at the NICHD in molecular biology studying membrane fusion properties, which lead to several publications. He then went on to Medical School at The George Washington University School of Medicine in Washington DC where he earned his M.D. degree.

Dr. Rashtian did his internship in Internal Medicine at Cedars Sinai Medical Center in Los Angeles and his training in Radiation Oncology at the Southern California Permanente Medical Group in Los Angeles. He has been involved in several research projects and was asked to give an oral presentation at the ASTRO (American Society of Therapeutic Radiology & Oncology) meeting regarding his research in breast cancer. He has also had several presentations at ASTRO regarding his research in lung cancer, breast cancer, sarcoma, and CNS. Dr. Rashtian’s expertise includes treating malignancies of the Lung, Head & Neck, Breast, CNS, Prostate, GI, Gyn, and Sarcoma. Additionally, he has a special interest in utilizing Stereotactic Body Radiation Therapy (SBRT) in treating malignancies.

Care Philosophy

Dr. Rashtian is a leader in the field of radiation oncology with a strong national reputation. He has given talks at both the regional and national stage. He hopes to bring his academic background and expertise to The CyberKnife at Newport Diagnostic Center and provide the latest technical and clinical advances the field has to offer.